Lincoln Pharmaceuticals Ltd AI Stock Analysis
Want to see IN:LINCOLN full AI Analyst Report?
Lincoln Pharmaceuticals Ltd (LINCOLN) AI Stock Analysis
Lincoln Pharmaceuticals Ltd
(NSE:LINCOLN)
Robust financial health led by a strong low-debt balance sheet and growth, plus attractive valuation, are the primary drivers; weak technical momentum from downtrend indicators limits upside.
Lincoln Pharmaceuticals Ltd (LINCOLN) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 10.44B
- Dividend Yield
- 0.34%
- Average Volume (3M)
- 2,909
- Price to Earnings (P/E)
- 10.8
- Beta (1Y)
- 0.94
- Revenue Growth
- 14.25%
- EPS Growth
- 21.11%
- Country
- India
- Employees
- 1,352
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Lincoln Pharmaceuticals Ltd Business Overview & Revenue Model
Company Description
Lincoln Pharmaceuticals Limited, established in 1979 and headquartered in Ahmedabad, India, is a pharmaceutical company engaged in the manufacturing and global distribution of its products. Its comprehensive product line addresses a wide array of med...
Lincoln Pharmaceuticals Ltd Financial Statement Overview
Summary
Strong balance sheet with minimal debt and growing equity, plus consistent revenue growth, offset by margin pressures and cash flow volatility.
Income Statement
72PositiveBalance Sheet
88Very PositiveCash Flow
68Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.46B | 6.71B | 6.23B | 5.81B | 5.05B | 4.68B |
| Gross Profit | 3.28B | 2.20B | 3.32B | 2.97B | 2.59B | 2.46B |
| EBITDA | 1.29B | 1.31B | 1.24B | 1.34B | 1.12B | 1.05B |
| Net Income | 968.95M | 878.94M | 823.46M | 933.05M | 728.99M | 693.55M |
Balance Sheet | ||||||
| Total Assets | 9.64B | 8.90B | 7.97B | 7.00B | 5.87B | 5.34B |
| Cash, Cash Equivalents and Short-Term Investments | 2.80B | 2.41B | 1.96B | 1.52B | 1.14B | 1.15B |
| Total Debt | 34.22M | 44.22M | 0 | 10.67M | 19.97M | 20.44M |
| Total Liabilities | 1.53B | 1.33B | 1.25B | 1.07B | 849.46M | 1.01B |
| Stockholders Equity | 8.12B | 7.58B | 6.72B | 5.93B | 5.02B | 4.33B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 815.07M | 737.71M | 237.41M | 249.80M | 306.07M |
| Operating Cash Flow | 0 | 1.07B | 930.15M | 632.17M | 392.62M | 761.32M |
| Investing Cash Flow | 0 | -996.37M | -789.47M | -573.42M | -366.43M | -780.80M |
| Financing Cash Flow | 0 | 8.16M | -64.02M | -51.80M | -45.01M | -25.56M |
Lincoln Pharmaceuticals Ltd Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LINCOLN, the sentiment is Neutral. The current price of 524.40 is above the 20-day moving average (MA) of 521.32, below the 50-day MA of 563.84, and below the 200-day MA of 594.10, indicating a neutral trend. The MACD of -11.68 indicates Negative momentum. The RSI at 45.74 is Neutral, neither overbought nor oversold. The STOCH value of 68.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:LINCOLN.
Lincoln Pharmaceuticals Ltd Peers Comparison
Overall Rating
IN:JAGSNPHARM78Outperform
IN:VENUSREM72Outperform
IN:SYNCOMF69Neutral
IN:LINCOLN66Neutral
IN:INDSWFTLAB51Neutral
IN:WANBURY48Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 78Outperform | INR 14.14B | 31.61 | ― | 1.86% | 11.71% | -26.92% | |
| 72Outperform | INR 20.83B | 17.14 | ― | 0.64% | 20.22% | 73.03% | |
| 69Neutral | INR 19.83B | 23.29 | ― | 0.47% | 0.44% | 48.60% | |
| 66Neutral | INR 10.50B | 10.77 | ― | 0.34% | 14.25% | 21.11% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 51Neutral | INR 30.41B | 35.76 | ― | ― | 66.39% | -72.31% | |
| 48Neutral | INR 6.23B | 11.75 | ― | ― | 7.45% | -6.56% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:LINCOLN | Lincoln Pharmaceuticals Ltd | 524.40 | -5.70 | -1.07% | |
| IN:INDSWFTLAB | Ind-Swift Laboratories Ltd. | 349.65 | 252.75 | 260.84% | |
| IN:JAGSNPHARM | Jagsonpal Pharmaceuticals Ltd. | 214.10 | 6.09 | 2.93% | |
| IN:SYNCOMF | Syncom Formulation (India) Ltd. | 21.10 | 4.80 | 29.46% | |
| IN:VENUSREM | Venus Remedies Limited | 1558.00 | 1006.06 | 182.28% | |
| IN:WANBURY | Wanbury Limited | 178.30 | -54.60 | -23.44% |
Lincoln Pharmaceuticals Ltd Corporate Events
Lincoln Pharmaceuticals sets September 30 virtual AGM, proposes dividend and director re-appointments
Lincoln Pharmaceuticals Ltd has scheduled its 32nd Annual General Meeting for September 30, 2026, at 11:00 a.m. IST, to be conducted via video conferencing or other audio-visual means, with the registered office in Ahmedabad deemed as the venue. The...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 30, 2026
